Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

doi:10.4239/wjd.v5.i6.854

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 6

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7103)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

520

WORD

254

HTML

3784

Tables (1-1)

136

Sum=4694

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1028

Download

1381

Sum=2409

Dec 15, 2014 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Dec 15, 2014; 5(6): 854-859
Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.854

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

Nasser Mikhail

Nasser Mikhail, Department of Medicine, Endocrine Division, OliveView-UCLA Medical Center, Sylmar, CA 91342, United States

Author contributions: Mikhail N solely contributed to this paper.

Correspondence to: Nasser Mikhail, MD, MSc, Department of Medicine, Endocrine Division, OliveView-UCLA Medical Center, 14445 Olive View Dr, Sylmar, CA 91342, United States. nmikhail@dhs.lacounty.gov

Telephone: +1-310-2607897

Received: July 2, 2014
Revised: July 19, 2014
Accepted: August 27, 2014
Published online: December 15, 2014

Core Tip

Core tip: Sodium-glucose co-transporter type 2 inhibitors are recently approved drugs for type 2 diabetes with unique mechanism of action. In this minireview, the author provides a practical approach on how to select the best candidates for these drugs.